Exanthem subitum; Sixth disease
Roseola is a viral infection that commonly affects infants and young children. It involves a pinkish-red skin rash and high fever.
Roseola is common in children ages 3 months to 4 years, and most common in those ages 6 months to 1 year.
It is caused by a virus called human herpesvirus 6 (HHV-6), although similar syndromes are possible with other viruses.
The time between becoming infected and the beginning of symptoms (incubation period) is 5 to 15 days.
The first symptoms include:
About 2 to 4 days after becoming sick, the child's fever lowers and a rash appears. This rash most often:
The rash lasts from a few hours to 2 to 3 days. It usually does not itch.
Your health care provider will perform a physical exam and ask questions about the child's medical history. The child may have swollen lymph nodes in the neck or back of the scalp.
There is no specific treatment for roseola. The disease most often gets better on its own without complications.
Acetaminophen (Tylenol) and cool sponge baths can help reduce the fever. Some children may have seizures when they get a high fever. If this occurs, call your health care provider or go to the closest emergency room.
Call your health care provider if your child:
Go to the emergency room or call the local emergency number (such as 911) if your child has convulsions.
Careful handwashing can help prevent the spread of the viruses that cause roseola.
Cherry J. Roseola Infantum (Exanthem Subitum). In: Cherry J, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, eds. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 7th ed. Philadelphia, PA: Elsevier Saunders; 2014:chap 59.
Caserta MT. Roseola (Human Herpes Viruses 6 and 7). In: Kliegman RM, Stanton BF, St Geme JW, Schor NF, eds. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Elsevier; 2016:chap 256.
Last reviewed on: 7/10/2015
Reviewed by: Neil K. Kaneshiro, MD, MHA, Clinical Assistant Professor of Pediatrics, University of Washington School of Medicine, Seattle, WA. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.